CJHK 112811 nocover - INFLIBNET Centreshodhganga.inflibnet.ac.in/bitstream/10603/5044/17/17... ·...
Transcript of CJHK 112811 nocover - INFLIBNET Centreshodhganga.inflibnet.ac.in/bitstream/10603/5044/17/17... ·...
88
REFERENCES 1. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900. 2. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J Clin 60, 277‐
300 (2010). 3. Boffetta, P. Human cancer from environmental pollutants: the epidemiological
evidence. Mutat Res 608, 157‐162 (2006). 4. Vineis, P., et al. Environmental tobacco smoke and risk of respiratory cancer and chronic
obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 330, 277 (2005).
5. Freudenheim, J.L., et al. Alcohol consumption and risk of lung cancer: a pooled analysis of cohort studies. Am J Clin Nutr 82, 657‐667 (2005).
6. Lee, I.M. Physical activity and cancer prevention‐‐data from epidemiologic studies. Med Sci Sports Exerc 35, 1823‐1827 (2003).
7. Vineis, P. & Husgafvel‐Pursiainen, K. Air pollution and cancer: biomarker studies in human populations. Carcinogenesis 26, 1846‐1855 (2005).
8. Boffetta, P. Epidemiology of environmental and occupational cancer. Oncogene 23, 6392‐6403 (2004).
9. Hwang, S.J., et al. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 113, 238‐243 (2003).
10. Bailey‐Wilson, J.E., et al. A major lung cancer susceptibility locus maps to chromosome 6q23‐25. Am J Hum Genet 75, 460‐474 (2004).
11. Thorgeirsson, T.E., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638‐642 (2008).
12. Hung, R.J., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452, 633‐637 (2008).
13. Amos, C.I., et al. Genome‐wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40, 616‐622 (2008).
14. Sher, T., Dy, G.K. & Adjei, A.A. Small cell lung cancer. Mayo Clin Proc 83, 355‐367 (2008). 15. Otterson, G., Lin, A. & Kay, F. Genetic etiology of lung cancer. Oncology (Williston Park)
6, 97‐104, 107; discussion 108, 111‐102 (1992). 16. Fernandez, F.G. & Battafarano, R.J. Large‐cell neuroendocrine carcinoma of the lung.
Cancer Control 13, 270‐275 (2006). 17. Travis, W.D., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with
clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22, 934‐944 (1998).
18. Lai, S.L., et al. MDR1 gene expression in lung cancer. J Natl Cancer Inst 81, 1144‐1150 (1989).
19. Filosso, P.L., et al. Long‐term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg 21, 913‐917 (2002).
20. Charloux, A., et al. International differences in epidemiology of lung adenocarcinoma. Lung Cancer 16, 133‐143 (1997).
21. Charloux, A., et al. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 26, 14‐23 (1997).
22. Travis WD, C.T., Corrin B, Shimosato Y, Brambilla E. World Health Organization International Histological Classification of Tumours. Histological Typing of Lung and Pleural Tumours. Vol. 3 (Springer‐Verlag, 1999).
89
23. William M. Thurlbeck, A.M.C. Pathology of the Lung. (1995). 24. Zhang, H. & Cai, B. The impact of tobacco on lung health in China. Respirology 8, 17‐21
(2003). 25. Arita, T., et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph
nodes. Thorax 50, 1267‐1269 (1995). 26. Marom, E.M., et al. Staging non‐small cell lung cancer with whole‐body PET. Radiology
212, 803‐809 (1999). 27. Weder, W., et al. Detection of extrathoracic metastases by positron emission
tomography in lung cancer. Ann Thorac Surg 66, 886‐892; discussion 892‐883 (1998). 28. Eloubeidi, M.A., et al. Endoscopic ultrasound‐guided fine needle aspiration of
mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg 79, 263‐268 (2005).
29. Kim, K., et al. Combined bronchoscopy, mediastinoscopy, and thoracotomy for lung cancer: who benefits? J Thorac Cardiovasc Surg 127, 850‐856 (2004).
30. Smith, R.A., et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001‐‐testing for early lung cancer detection. CA Cancer J Clin 51, 38‐75; quiz 77‐80 (2001).
31. Molina, J.R., Yang, P., Cassivi, S.D., Schild, S.E. & Adjei, A.A. Non‐small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83, 584‐594 (2008).
32. Pfister, D.G., et al. American Society of Clinical Oncology treatment of unresectable non‐small‐cell lung cancer guideline: update 2003. J Clin Oncol 22, 330‐353 (2004).
33. Arriagada, R., et al. Cisplatin‐based adjuvant chemotherapy in patients with completely resected non‐small‐cell lung cancer. N Engl J Med 350, 351‐360 (2004).
34. Winton, T., et al. Vinorelbine plus cisplatin vs. observation in resected non‐small‐cell lung cancer. N Engl J Med 352, 2589‐2597 (2005).
35. Douillard, J.Y., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB‐IIIA non‐small‐cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7, 719‐727 (2006).
36. Strauss, G.M., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non‐small‐cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26, 5043‐5051 (2008).
37. Xu, G., Rong, T. & Lin, P. Adjuvant chemotherapy following radical surgery for non‐small‐cell lung cancer: a randomized study on 70 patients. Chin Med J (Engl) 113, 617‐620 (2000).
38. Mineo, T.C., Ambrogi, V., Corsaro, V. & Roselli, M. Postoperative adjuvant therapy for stage IB non‐small‐cell lung cancer. Eur J Cardiothorac Surg 20, 378‐384 (2001).
39. Nakagawa, K., et al. Randomised study of adjuvant chemotherapy for completely resected p‐stage I‐IIIA non‐small cell lung cancer. Br J Cancer 95, 817‐821 (2006).
40. Imaizumi, M. Postoperative adjuvant cisplatin, vindesine, plus uracil‐tegafur chemotherapy increased survival of patients with completely resected p‐stage I non‐small cell lung cancer. Lung Cancer 49, 85‐94 (2005).
41. Mok, T.S., et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361, 947‐957 (2009).
90
42. Mitsudomi, T., et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11, 121‐128 (2010).
43. Maemondo, M., et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. N Engl J Med 362, 2380‐2388 (2010).
44. Giaccone, G., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non‐small‐cell lung cancer: a phase III trial‐‐INTACT 1. J Clin Oncol 22, 777‐784 (2004).
45. Herbst, R.S., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non‐small‐cell lung cancer: a phase III trial‐‐INTACT 2. J Clin Oncol 22, 785‐794 (2004).
46. Herbst, R.S., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI‐774) combined with carboplatin and paclitaxel chemotherapy in advanced non‐small‐cell lung cancer. J Clin Oncol 23, 5892‐5899 (2005).
47. Gatzemeier, U., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non‐small‐cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25, 1545‐1552 (2007).
48. Kelly, K., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non‐small‐cell lung cancer: SWOG S0023. J Clin Oncol 26, 2450‐2456 (2008).
49. Takeda, K., et al. Randomized phase III trial of platinum‐doublet chemotherapy followed by gefitinib compared with continued platinum‐doublet chemotherapy in Japanese patients with advanced non‐small‐cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 28, 753‐760 (2010).
50. Cappuzzo, F., et al. Erlotinib as maintenance treatment in advanced non‐small‐cell lung cancer: a multicentre, randomised, placebo‐controlled phase 3 study. Lancet Oncol 11, 521‐529 (2010).
51. Miller VA, O.C.P., Soh C, Kabbinavar F. A randomized, double‐blind, placebo‐controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first‐line treatment of locally advanced, recurrent, or metastatic non‐small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 27, LBA8002 (2009).
52. Kelsey, C.R., et al. Local recurrence after surgery for early stage lung cancer: an 11‐year experience with 975 patients. Cancer 115, 5218‐5227 (2009).
53. Saynak, M., Higginson, D.S., Morris, D.E. & Marks, L.B. Current status of postoperative radiation for non‐small‐cell lung cancer. Semin Radiat Oncol 20, 192‐200 (2010).
54. Sandler, A.B., et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first‐line advanced, unresectable non‐small‐cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 27, 1405‐1412 (2009).
55. Stein, R.A. & Staros, J.V. Evolutionary analysis of the ErbB receptor and ligand families. J Mol Evol 50, 397‐412 (2000).
56. Yarden, Y. & Sliwkowski, M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127‐137 (2001).
57. Citri, A., Skaria, K.B. & Yarden, Y. The deaf and the dumb: the biology of ErbB‐2 and ErbB‐3. Exp Cell Res 284, 54‐65 (2003).
58. van der Geer, P., Hunter, T. & Lindberg, R.A. Receptor protein‐tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10, 251‐337 (1994).
59. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211‐225 (2000).
91
60. Schlessinger, J. Ligand‐induced, receptor‐mediated dimerization and activation of EGF receptor. Cell 110, 669‐672 (2002).
61. Lemmon, M.A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117‐1134 (2010).
62. Waterfield, M. Cracking the mild, difficult and fiendish codes within and downstream of the EGFR to link diagnostics and therapeutics. Biochem Soc Trans 35, 1‐6 (2007).
63. Citri, A. & Yarden, Y. EGF‐ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7, 505‐516 (2006).
64. Ferguson, K.M. Structure‐based view of epidermal growth factor receptor regulation. Annu Rev Biophys 37, 353‐373 (2008).
65. Pao, W., Miller, V.A. & Kris, M.G. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non‐small cell lung cancer (NSCLC). Semin Cancer Biol 14, 33‐40 (2004).
66. Wakeling, A.E., et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62, 5749‐5754 (2002).
67. Pollack, V.A., et al. Inhibition of epidermal growth factor receptor‐associated tyrosine phosphorylation in human carcinomas with CP‐358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291, 739‐748 (1999).
68. Perez‐Soler, R., et al. Determinants of tumor response and survival with erlotinib in patients with non‐‐small‐cell lung cancer. J Clin Oncol 22, 3238‐3247 (2004).
69. Hidalgo, M., et al. Phase I and pharmacologic study of OSI‐774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19, 3267‐3279 (2001).
70. Giaccone, G., et al. Erlotinib for frontline treatment of advanced non‐small cell lung cancer: a phase II study. Clin Cancer Res 12, 6049‐6055 (2006).
71. Jackman, D.M., et al. Phase II clinical trial of chemotherapy‐naive patients > or = 70 years of age treated with erlotinib for advanced non‐small‐cell lung cancer. J Clin Oncol 25, 760‐766 (2007).
72. Gridelli, C., et al. Erlotinib in non‐small cell lung cancer treatment: current status and future development. Oncologist 12, 840‐849 (2007).
73. Massarelli, E., et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non‐small‐cell lung cancer. Lung Cancer 39, 55‐61 (2003).
74. Shepherd, F.A., et al. Erlotinib in previously treated non‐small‐cell lung cancer. N Engl J Med 353, 123‐132 (2005).
75. Arteaga, C.L. ErbB‐targeted therapeutic approaches in human cancer. Exp Cell Res 284, 122‐130 (2003).
76. Luetteke, N.C., et al. The mouse waved‐2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev 8, 399‐413 (1994).
77. Lynch, T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non‐small‐cell lung cancer to gefitinib. N Engl J Med 350, 2129‐2139 (2004).
78. Paez, J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497‐1500 (2004).
79. Sahoo, R., et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer (2011).
80. Lopez, M.F., et al. High‐throughput profiling of the mitochondrial proteome using affinity fractionation and automation. Electrophoresis 21, 3427‐3440 (2000).
92
81. Hu, W., Wu, W., Kobayashi, R. & Kavanagh, J.J. Proteomics in cancer screening and management in gynecologic cancer. Curr Oncol Rep 6, 456‐462 (2004).
82. Bichsel, V.E., Liotta, L.A. & Petricoin, E.F., 3rd. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J 7, 69‐78 (2001).
83. Walter, G., Bussow, K., Lueking, A. & Glokler, J. High‐throughput protein arrays: prospects for molecular diagnostics. Trends Mol Med 8, 250‐253 (2002).
84. Li, J., Zhang, Z., Rosenzweig, J., Wang, Y.Y. & Chan, D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48, 1296‐1304 (2002).
85. Tangrea, M.A., et al. Expression microdissection: operator‐independent retrieval of cells for molecular profiling. Diagn Mol Pathol 13, 207‐212 (2004).
86. Alaoui‐Jamali, M.A., Dupre, I. & Qiang, H. Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. Drug Resist Updat 7, 245‐255 (2004).
87. Kopf, E. & Zharhary, D. Antibody arrays‐‐an emerging tool in cancer proteomics. Int J Biochem Cell Biol 39, 1305‐1317 (2007).
88. Hudelist, G., et al. Use of high‐throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue. Breast Cancer Res Treat 86, 281‐291 (2004).
89. Misek, D.E., Imafuku, Y. & Hanash, S.M. Application of proteomic technologies to tumor analysis. Pharmacogenomics 5, 1129‐1137 (2004).
90. Sjoholt, G., et al. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Curr Drug Targets 6, 631‐646 (2005).
91. Rajapakse, J.C., Duan, K.B. & Yeo, W.K. Proteomic cancer classification with mass spectrometry data. Am J Pharmacogenomics 5, 281‐292 (2005).
92. Stewart, J.J., et al. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 5, 433‐443 (2006).
93. Amanchy, R., Kalume, D.E., Iwahori, A., Zhong, J. & Pandey, A. Phosphoproteome analysis of HeLa cells using stable isotope labeling with amino acids in cell culture (SILAC). J Proteome Res 4, 1661‐1671 (2005).
94. Amanchy, R., Kalume, D.E. & Pandey, A. Stable isotope labeling with amino acids in cell culture (SILAC) for studying dynamics of protein abundance and posttranslational modifications. Sci STKE 2005, pl2 (2005).
95. Guha, U., et al. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer‐specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A 105, 14112‐14117 (2008).
96. Kristiansen, T.Z., Harsha, H.C., Gronborg, M., Maitra, A. & Pandey, A. Differential membrane proteomics using 18O‐labeling to identify biomarkers for cholangiocarcinoma. J Proteome Res 7, 4670‐4677 (2008).
97. Ong, S.E., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1, 376‐386 (2002).
98. Taylor, B.S., Varambally, S. & Chinnaiyan, A.M. A systems approach to model metastatic progression. Cancer Res 66, 5537‐5539 (2006).
93
99. Denkert, C., et al. Mass spectrometry‐based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 66, 10795‐10804 (2006).
100. Harsha, H.C., et al. Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J Proteome Res 7, 4651‐4658 (2008).
101. Harsha, H.C., et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6, e1000046 (2009).
102. Harsha, H.C., Molina, H. & Pandey, A. Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nat Protoc 3, 505‐516 (2008).
103. Ranganathan, P., Harsha, H.C. & Pandey, A. Molecular alterations in exocrine neoplasms of the pancreas. Arch Pathol Lab Med 133, 405‐412 (2009).
104. Agyeman, A.S., et al. Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane‐treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res Treat (2011).
105. Amanchy, R., et al. Identification of c‐Src tyrosine kinase substrates in platelet‐derived growth factor receptor signaling. Mol Oncol 3, 439‐450 (2009).
106. Bose, R., et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci U S A 103, 9773‐9778 (2006).
107. Chaerkady, R. & Pandey, A. Quantitative proteomics for identification of cancer biomarkers. Proteomics Clin Appl 1, 1080‐1089 (2007).
108. Chen, H., et al. Proteomic characterization of Her2/neu‐overexpressing breast cancer cells. Proteomics 10, 3800‐3810 (2010).
109. Gronborg, M., et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5, 157‐171 (2006).
110. Zhong, J., Molina, H. & Pandey, A. Phosphoproteomics. Curr Protoc Protein Sci Chapter 24, Unit 24 24 (2007).
111. Kandasamy, K., Pandey, A. & Molina, H. Evaluation of several MS/MS search algorithms for analysis of spectra derived from electron transfer dissociation experiments. Anal Chem 81, 7170‐7180 (2009).
112. Kim, M.S., Zhong, J., Kandasamy, K., Delanghe, B. & Pandey, A. Systematic evaluation of alternating CID and ETD fragmentation for phosphorylated peptides. Proteomics 11, 2568‐2572 (2011).
113. Molina, H., Horn, D.M., Tang, N., Mathivanan, S. & Pandey, A. Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 104, 2199‐2204 (2007).
114. Molina, H., Matthiesen, R., Kandasamy, K. & Pandey, A. Comprehensive comparison of collision induced dissociation and electron transfer dissociation. Anal Chem 80, 4825‐4835 (2008).
115. Fujii, K., et al. Clinical‐scale high‐throughput human plasma proteome analysis: lung adenocarcinoma. Proteomics 5, 1150‐1159 (2005).
116. Guergova‐Kuras, M., et al. Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries. Mol Cell Proteomics (2011).
117. Taguchi, A., et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 20, 289‐299 (2011).
118. Sudhir, P.R., et al. Phosphoproteomics identifies oncogenic Ras signaling targets and their involvement in lung adenocarcinomas. PLoS One 6, e20199 (2011).
119. Rahman, S.M., et al. Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer Res 71, 3009‐3017 (2011).
94
120. Machida, K., Mayer, B.J. & Nollau, P. Profiling the global tyrosine phosphorylation state. Mol Cell Proteomics 2, 215‐233 (2003).
121. Lim, Y.P. Mining the tumor phosphoproteome for cancer markers. Clin Cancer Res 11, 3163‐3169 (2005).
122. Lee, K.B. & Pi, K.B. [Comparative proteomic analysis of cancerous and adjacent normal lung tissues]. Biomed Khim 56, 663‐673 (2010).
123. Watowich, S.S., et al. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol 12, 91‐128 (1996).
124. Fadden, P. & Haystead, T.A. Quantitative and selective fluorophore labeling of phosphoserine on peptides and proteins: characterization at the attomole level by capillary electrophoresis and laser‐induced fluorescence. Anal Biochem 225, 81‐88 (1995).
125. Mann, M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol 7, 952‐958 (2006).
126. Gruhler, S. & Kratchmarova, I. Stable isotope labeling by amino acids in cell culture (SILAC). Methods Mol Biol 424, 101‐111 (2008).
127. Emadali, A. & Gallagher‐Gambarelli, M. [Quantitative proteomics by SILAC: practicalities and perspectives for an evolving approach]. Med Sci (Paris) 25, 835‐842 (2009).
128. von Haller, P.D., et al. The application of new software tools to quantitative protein profiling via isotope‐coded affinity tag (ICAT) and tandem mass spectrometry: II. Evaluation of tandem mass spectrometry methodologies for large‐scale protein analysis, and the application of statistical tools for data analysis and interpretation. Mol Cell Proteomics 2, 428‐442 (2003).
129. Everley, P.A., Krijgsveld, J., Zetter, B.R. & Gygi, S.P. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics 3, 729‐735 (2004).
130. Ong, S.E., Mittler, G. & Mann, M. Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. Nat Methods 1, 119‐126 (2004).
131. Pimienta, G., Chaerkady, R. & Pandey, A. SILAC for global phosphoproteomic analysis. Methods Mol Biol 527, 107‐116, x (2009).
132. Cuomo, A. & Bonaldi, T. Systems biology "on‐the‐fly": SILAC‐based quantitative proteomics and RNAi approach in Drosophila melanogaster. Methods Mol Biol 662, 59‐78 (2010).
133. Yang, Y., et al. Identifying targets of miR‐143 using a SILAC‐based proteomic approach. Mol Biosyst 6, 1873‐1882 (2010).
134. de Godoy, L.M., et al. Status of complete proteome analysis by mass spectrometry: SILAC labeled yeast as a model system. Genome Biol 7, R50 (2006).
135. Dilworth, D.J., et al. QTIPS: a novel method of unsupervised determination of isotopic amino acid distribution in SILAC experiments. J Am Soc Mass Spectrom 21, 1417‐1422 (2010).
136. Kruger, M., et al. SILAC mouse for quantitative proteomics uncovers kindlin‐3 as an essential factor for red blood cell function. Cell 134, 353‐364 (2008).
137. Sury, M.D., Chen, J.X. & Selbach, M. The SILAC fly allows for accurate protein quantification in vivo. Mol Cell Proteomics 9, 2173‐2183 (2010).
138. Hanke, S., Besir, H., Oesterhelt, D. & Mann, M. Absolute SILAC for accurate quantitation of proteins in complex mixtures down to the attomole level. J Proteome Res 7, 1118‐1130 (2008).
95
139. Doherty, M.K., Hammond, D.E., Clague, M.J., Gaskell, S.J. & Beynon, R.J. Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC. J Proteome Res 8, 104‐112 (2009).
140. Schwanhausser, B., Gossen, M., Dittmar, G. & Selbach, M. Global analysis of cellular protein translation by pulsed SILAC. Proteomics 9, 205‐209 (2009).
141. Schuchardt, S. & Borlak, J. Quantitative mass spectrometry to investigate epidermal growth factor receptor phosphorylation dynamics. Mass Spectrom Rev 27, 51‐65 (2008).
142. Moro, L., et al. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion‐dependent cell survival. EMBO J 17, 6622‐6632 (1998).
143. Guo, L., et al. Studies of ligand‐induced site‐specific phosphorylation of epidermal growth factor receptor. J Am Soc Mass Spectrom 14, 1022‐1031 (2003).
144. Olsen, J.V., et al. Global, in vivo, and site‐specific phosphorylation dynamics in signaling networks. Cell 127, 635‐648 (2006).
145. Harris, D.L. & Joyce, N.C. Protein tyrosine phosphatase, PTP1B, expression and activity in rat corneal endothelial cells. Mol Vis 13, 785‐796 (2007).
146. Lombardo, C.R., Consler, T.G. & Kassel, D.B. In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by c‐src: identification of phosphorylation sites and c‐src SH2 domain binding sites. Biochemistry 34, 16456‐16466 (1995).
147. Chattopadhyay, A., Vecchi, M., Ji, Q., Mernaugh, R. & Carpenter, G. The role of individual SH2 domains in mediating association of phospholipase C‐gamma1 with the activated EGF receptor. J Biol Chem 274, 26091‐26097 (1999).
148. Carpenter, G. The EGF receptor: a nexus for trafficking and signaling. Bioessays 22, 697‐707 (2000).
149. Yudushkin, I.A., et al. Live‐cell imaging of enzyme‐substrate interaction reveals spatial regulation of PTP1B. Science 315, 115‐119 (2007).
150. Blagoev, B., et al. A proteomics strategy to elucidate functional protein‐protein interactions applied to EGF signaling. Nat Biotechnol 21, 315‐318 (2003).
151. Schulze, W.X., Deng, L. & Mann, M. Phosphotyrosine interactome of the ErbB‐receptor kinase family. Mol Syst Biol 1, 2005 0008 (2005).
152. Pandey, A., et al. Cloning of a novel phosphotyrosine binding domain containing molecule, Odin, involved in signaling by receptor tyrosine kinases. Oncogene 21, 8029‐8036 (2002).
153. Kratchmarova, I., Blagoev, B., Haack‐Sorensen, M., Kassem, M. & Mann, M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 308, 1472‐1477 (2005).
154. Ibarrola, N., Kalume, D.E., Gronborg, M., Iwahori, A. & Pandey, A. A proteomic approach for quantitation of phosphorylation using stable isotope labeling in cell culture. Anal Chem 75, 6043‐6049 (2003).
155. Mertins, P., et al. Investigation of protein‐tyrosine phosphatase 1B function by quantitative proteomics. Mol Cell Proteomics 7, 1763‐1777 (2008).
156. Blagoev, B., Ong, S.E., Kratchmarova, I. & Mann, M. Temporal analysis of phosphotyrosine‐dependent signaling networks by quantitative proteomics. Nat Biotechnol 22, 1139‐1145 (2004).
157. Zhang, Y., et al. Time‐resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics 4, 1240‐1250 (2005).
96
158. Rikova, K., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190‐1203 (2007).
159. Rush, J., et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23, 94‐101 (2005).
160. Fujishita, T., et al. Sensitivity of non‐small‐cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel. Oncology 64, 399‐406 (2003).
161. Tracy, S., et al. Gefitinib induces apoptosis in the EGFRL858R non‐small‐cell lung cancer cell line H3255. Cancer Res 64, 7241‐7244 (2004).
162. Engelman, J.A., et al. ErbB‐3 mediates phosphoinositide 3‐kinase activity in gefitinib‐sensitive non‐small cell lung cancer cell lines. Proc Natl Acad Sci U S A 102, 3788‐3793 (2005).
163. Sethi, G., Ahn, K.S., Chaturvedi, M.M. & Aggarwal, B.B. Epidermal growth factor (EGF) activates nuclear factor‐kappaB through IkappaBalpha kinase‐independent but EGF receptor‐kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene 26, 7324‐7332 (2007).
164. Gadgeel, S.M., et al. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase‐2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. Cancer 110, 2775‐2784 (2007).
165. Taouatas, N., et al. Strong cation exchange‐based fractionation of Lys‐N‐generated peptides facilitates the targeted analysis of post‐translational modifications. Mol Cell Proteomics 8, 190‐200 (2009).
166. Pinkse, M.W., Lemeer, S. & Heck, A.J. A protocol on the use of titanium dioxide chromatography for phosphoproteomics. Methods Mol Biol 753, 215‐228 (2011).
167. Cox, J., et al. A practical guide to the MaxQuant computational platform for SILAC‐based quantitative proteomics. Nat Protoc 4, 698‐705 (2009).
168. Cox, J., et al. Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment. J Proteome Res 10, 1794‐1805 (2011).
169. Hunter, T. A thousand and one protein kinases. Cell 50, 823‐829 (1987). 170. Mustelin, T., Abraham, R.T., Rudd, C.E., Alonso, A. & Merlo, J.J. Protein tyrosine
phosphorylation in T cell signaling. Front Biosci 7, d918‐969 (2002). 171. Mustelin, T., et al. Protein tyrosine phosphatases. Front Biosci 7, d85‐142 (2002). 172. Hunter, T. Signaling‐‐2000 and beyond. Cell 100, 113‐127 (2000). 173. Pawson, T. & Nash, P. Assembly of cell regulatory systems through protein interaction
domains. Science 300, 445‐452 (2003). 174. Hunter, T. & Sefton, B.M. Transforming gene product of Rous sarcoma virus
phosphorylates tyrosine. Proc Natl Acad Sci U S A 77, 1311‐1315 (1980). 175. Engelman, J.A. & Cantley, L.C. The role of the ErbB family members in non‐small cell lung
cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12, 4372s‐4376s (2006).
176. Wangpaichitr, M., et al. Inhibition of mTOR restores cisplatin sensitivity through down‐regulation of growth and anti‐apoptotic proteins. Eur J Pharmacol 591, 124‐127 (2008).
177. Restuccia, D.F. & Hemmings, B.A. From man to mouse and back again: advances in defining tumor AKTivities in vivo. Dis Model Mech 3, 705‐720 (2010).
178. Guertin, D.A. & Sabatini, D.M. Defining the role of mTOR in cancer. Cancer Cell 12, 9‐22 (2007).
179. Gomez‐Martin, C., Rubio‐Viqueira, B. & Hidalgo, M. Current status of mammalian target of rapamycin inhibitors in lung cancer. Clin Lung Cancer 7 Suppl 1, S13‐18 (2005).
97
180. Byfield, M.P., Murray, J.T. & Backer, J.M. hVps34 is a nutrient‐regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 280, 33076‐33082 (2005).
181. Sonenberg, N. & Hinnebusch, A.G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731‐745 (2009).
182. Ruvinsky, I. & Meyuhas, O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 31, 342‐348 (2006).
183. Raught, B. & Gingras, A.C. eIF4E activity is regulated at multiple levels. Int J Biochem Cell Biol 31, 43‐57 (1999).
184. Raught, B., et al. Serum‐stimulated, rapamycin‐sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J 19, 434‐444 (2000).
185. Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13, 9‐22 (1999).
186. Joukov, V., et al. A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. EMBO J 15, 290‐298 (1996).
187. Yuan, A., et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non‐small‐cell lung cancer. J Clin Oncol 19, 432‐441 (2001).
188. Fontanini, G., et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non‐small cell lung carcinoma. Clin Cancer Res 3, 861‐865 (1997).
189. Ferrara, N., Gerber, H.P. & LeCouter, J. The biology of VEGF and its receptors. Nat Med 9, 669‐676 (2003).
190. Rocha‐Lima, C.M., Soares, H.P., Raez, L.E. & Singal, R. EGFR targeting of solid tumors. Cancer Control 14, 295‐304 (2007).
191. Pennell, N.A. & Lynch, T.J., Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14, 399‐411 (2009).
192. Landgren, E., Blume‐Jensen, P., Courtneidge, S.A. & Claesson‐Welsh, L. Fibroblast growth factor receptor‐1 regulation of Src family kinases. Oncogene 10, 2027‐2035 (1995).
193. Volm, M., Koomagi, R., Mattern, J. & Stammler, G. Prognostic value of basic fibroblast growth factor and its receptor (FGFR‐1) in patients with non‐small cell lung carcinomas. Eur J Cancer 33, 691‐693 (1997).
194. Takanami, I., et al. The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers. Eur J Cancer 32A, 1504‐1509 (1996).
195. Slodkowska, J., Sikora, J., Roszkowski‐Sliz, K., Radomyski, A. & Androsiuk, W. Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer. Anal Quant Cytol Histol 22, 398‐402 (2000).
196. Dey, J.H., et al. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 70, 4151‐4162 (2010).
197. Semrad, T.J. & Mack, P.C. Fibroblast Growth Factor Signaling in Non‐Small Cell Lung Cancer. Clin Lung Cancer (2011).
198. Himanen, J.P. & Nikolov, D.B. Eph receptors and ephrins. Int J Biochem Cell Biol 35, 130‐134 (2003).
98
199. Tang, X.X., Brodeur, G.M., Campling, B.G. & Ikegaki, N. Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin‐B ligands in human small cell lung carcinoma. Clin Cancer Res 5, 455‐460 (1999).
200. Hafner, C., et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 50, 490‐499 (2004).
201. Yu, J., et al. The kinase defective EPHB6 receptor tyrosine kinase activates MAP kinase signaling in lung adenocarcinoma. Int J Oncol 35, 175‐179 (2009).
202. Sos, M.L., et al. Predicting drug susceptibility of non‐small cell lung cancers based on genetic lesions. J Clin Invest 119, 1727‐1740 (2009).
203. Ding, L., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069‐1075 (2008).
204. Nakamoto, M. & Bergemann, A.D. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59, 58‐67 (2002).
205. Foo, S.S., et al. Ephrin‐B2 controls cell motility and adhesion during blood‐vessel‐wall assembly. Cell 124, 161‐173 (2006).
206. Ogawa, K., et al. The ephrin‐A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19, 6043‐6052 (2000).
207. Stahl, S., et al. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro‐survival signaling through Akt1‐mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566‐2578 (2011).
208. Nasarre, P., Potiron, V., Drabkin, H. & Roche, J. Guidance molecules in lung cancer. Cell Adh Migr 4, 130‐145 (2010).
209. Liu, D., et al. Down‐regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway. J Cancer Res Clin Oncol 137, 1629‐1640 (2011).
210. Song, L., Rawal, B., Nemeth, J.A. & Haura, E.B. JAK1 activates STAT3 activity in non‐small‐cell lung cancer cells and IL‐6 neutralizing antibodies can suppress JAK1‐STAT3 signaling. Mol Cancer Ther 10, 481‐494 (2011).
211. Zhang, Z.Y. Protein‐tyrosine phosphatases: biological function, structural characteristics, and mechanism of catalysis. Crit Rev Biochem Mol Biol 33, 1‐52 (1998).
212. Andersen, J.N., et al. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J 18, 8‐30 (2004).
213. Alonso, A., et al. Protein tyrosine phosphatases in the human genome. Cell 117, 699‐711 (2004).
214. Gandhi, T.K., et al. Analysis of the human protein interactome and comparison with yeast, worm and fly interaction datasets. Nat Genet 38, 285‐293 (2006).
215. Ostman, A., Hellberg, C. & Bohmer, F.D. Protein‐tyrosine phosphatases and cancer. Nat Rev Cancer 6, 307‐320 (2006).
216. Easty, D., Gallagher, W. & Bennett, D.C. Protein tyrosine phosphatases, new targets for cancer therapy. Curr Cancer Drug Targets 6, 519‐532 (2006).
217. Jallal, B., Schlessinger, J. & Ullrich, A. Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu‐overexpressing human tumor cells. J Biol Chem 267, 4357‐4363 (1992).
218. Ikuta, S., et al. Expression of cytoskeletal‐associated protein tyrosine phosphatase PTPH1 mRNA in human hepatocellular carcinoma. J Gastroenterol 29, 727‐732 (1994).
219. Warabi, M., Nemoto, T., Ohashi, K., Kitagawa, M. & Hirokawa, K. Expression of protein tyrosine phosphatases and its significance in esophageal cancer. Exp Mol Pathol 68, 187‐195 (2000).
99
220. Wu, C.W., et al. PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma. Anticancer Res 26, 1643‐1649 (2006).
221. Hou, S.W., et al. PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ‐mediated interaction. Cancer Res 70, 2901‐2910 (2010).
222. De Leon, G., Sherry, T.C. & Krucher, N.A. Reduced expression of PNUTS leads to activation of Rb‐phosphatase and caspase‐mediated apoptosis. Cancer Biol Ther 7, 833‐841 (2008).
223. Grana, X. Downregulation of the phosphatase nuclear targeting subunit (PNUTS) triggers pRB dephosphorylation and apoptosis in pRB positive tumor cell lines. Cancer Biol Ther 7, 842‐844 (2008).
224. den Hertog, J., Tracy, S. & Hunter, T. Phosphorylation of receptor protein‐tyrosine phosphatase alpha on Tyr789, a binding site for the SH3‐SH2‐SH3 adaptor protein GRB‐2 in vivo. EMBO J 13, 3020‐3032 (1994).
225. Su, J., Batzer, A. & Sap, J. Receptor tyrosine phosphatase R‐PTP‐alpha is tyrosine‐phosphorylated and associated with the adaptor protein Grb2. J Biol Chem 269, 18731‐18734 (1994).
226. Su, J., Yang, L.T. & Sap, J. Association between receptor protein‐tyrosine phosphatase RPTPalpha and the Grb2 adaptor. Dual Src homology (SH) 2/SH3 domain requirement and functional consequences. J Biol Chem 271, 28086‐28096 (1996).
227. Ertmer, A., et al. The anticancer drug imatinib induces cellular autophagy. Leukemia 21, 936‐942 (2007).
228. Schmid, K., et al. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer 103, 622‐628 (2010).
229. Blancquaert, S., et al. cAMP‐dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4. Mol Endocrinol 24, 1453‐1468 (2010).
230. Armour, S.M., et al. Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. Aging (Albany NY) 1, 515‐528 (2009).
231. Behrends, C., Sowa, M.E., Gygi, S.P. & Harper, J.W. Network organization of the human autophagy system. Nature 466, 68‐76 (2010).
232. Kirkin, V., McEwan, D.G., Novak, I. & Dikic, I. A role for ubiquitin in selective autophagy. Mol Cell 34, 259‐269 (2009).
233. Mizushima, N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol 22, 132‐139 (2010).
234. Tan, B.C. & Lee, S.C. Nek9, a novel FACT‐associated protein, modulates interphase progression. J Biol Chem 279, 9321‐9330 (2004).
235. Belham, C., et al. A mitotic cascade of NIMA family kinases. Nercc1/Nek9 activates the Nek6 and Nek7 kinases. J Biol Chem 278, 34897‐34909 (2003).
236. Chen, Y. & Klionsky, D.J. The regulation of autophagy ‐ unanswered questions. J Cell Sci 124, 161‐170 (2011).
237. Ling, Y.H., Lin, R. & Perez‐Soler, R. Erlotinib induces mitochondrial‐mediated apoptosis in human H3255 non‐small‐cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation‐dependent activation of BAX and BAK. Mol Pharmacol 74, 793‐806 (2008).
238. Fimia, G.M. & Piacentini, M. Regulation of autophagy in mammals and its interplay with apoptosis. Cell Mol Life Sci 67, 1581‐1588 (2010).
100
239. Kim, Y.Y., et al. Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense. Cancer Res 69, 8455‐8462 (2009).
240. Kantidakis, T., Ramsbottom, B.A., Birch, J.L., Dowding, S.N. & White, R.J. mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1. Proc Natl Acad Sci U S A 107, 11823‐11828 (2010).
241. Staber, P.B., et al. The oncoprotein NPM‐ALK of anaplastic large‐cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood 110, 3374‐3383 (2007).
242. Farras, R., et al. JunB breakdown in mid‐/late G2 is required for down‐regulation of cyclin A2 levels and proper mitosis. Mol Cell Biol 28, 4173‐4187 (2008).
243. Wu, T.T. & Castle, J.D. Tyrosine phosphorylation of selected secretory carrier membrane proteins, SCAMP1 and SCAMP3, and association with the EGF receptor. Mol Biol Cell 9, 1661‐1674 (1998).
244. Ohno, H., et al. Localization of p0071‐interacting proteins, plakophilin‐related armadillo‐repeat protein‐interacting protein (PAPIN) and ERBIN, in epithelial cells. Oncogene 21, 7042‐7049 (2002).
245. Kamei, T., et al. C‐Cbl protein in human cancer tissues is frequently tyrosine phosphorylated in a tumor‐specific manner. Int J Oncol 17, 335‐339 (2000).
246. Levkowitz, G., et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c‐Cbl/Sli‐1. Mol Cell 4, 1029‐1040 (1999).
247. Hosaka, T., et al. Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c‐Cbl. Anticancer Res 27, 2253‐2263 (2007).
248. Ravid, T., Heidinger, J.M., Gee, P., Khan, E.M. & Goldkorn, T. c‐Cbl‐mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes. J Biol Chem 279, 37153‐37162 (2004).
249. Padron, D., et al. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down‐regulation but are efficiently internalized. Cancer Res 67, 7695‐7702 (2007).
250. Dowler, S., Montalvo, L., Cantrell, D., Morrice, N. & Alessi, D.R. Phosphoinositide 3‐kinase‐dependent phosphorylation of the dual adaptor for phosphotyrosine and 3‐phosphoinositides by the Src family of tyrosine kinase. Biochem J 349, 605‐610 (2000).
101
APPENDIX
Figure A.: Signaling pathway map of the EGFR pathway part of the curation effort of our lab as part of the NetPath project in mapping the entire pathway. Inset in red is a zoomed image of the pathway indicating the complexity of the pathway and the numerous cross talks with other adapter and signaling molecules
102
Table A List of peptides that were either unchanged (Unc) or activated (Act) on EGF treatment but were dephosphorylated on Erlotinib treatment. The phosphorylation sites are indicated by pY, pS or pT. L=light state, M=medium state and H=heavy state. Other post translational modifications are Oxidation (ox) and Acetylation (Ac)
Name Gene
Symbol EGF
Status Modified Sequence M/L H/L H/M
General transcription factor 3C polypeptide 1 GTF3C1 Unc KNpSSTDQGpSDEEGSLQK 1.8 0.6 0.4 Serine/threonine-protein kinase 3 STK3 Unc ELEEEEENpSDEDELDSHTM(ox)VK 1.2 0.7 0.6 Epidermal growth factor receptor substrate 15-like 1 EPS15L1 Unc STPpSHGSVSSLNSTGSLpSPK 0.9 0.4 0.5
Calpastatin isoform F CAST
Unc
EGITGPPADSSKPIGPDDAIDALSSDFTCGSPpTAAGK
0.9 0.5 0.6
Unc
EGITGPPADSSKPIGPDDAIDALSSDFTCGpSPTAAGK
0.8 0.4 0.5
la-related protein 7 LARP7 Unc SpSSEDAESLAPR 1.3 0.3 0.2 Unc SSpSEDAESLAPR 1.4 0.2 0.1
Neurofibromin isoform 1 NF1 Unc pSFDHLISDTK 1.1 0.8 0.7
182 kDa tankyrase-1-binding protein TNKS1BP1 Unc HNGpSLSPGLEARDPLEAR 1.3 0.8 0.6 Unc RFpSEGVLQSPSQDQEK 1.2 0.7 0.6 Unc RFpSEGVLQpSPSQDQEK 1.2 0.5 0.4
Hypothetical protein LOC57648 KIAA1522 Unc GpSPSGGSTAEASDTLSIR 1.2 0.8 0.7 Unc CSLHSApSPApSVR 1.0 0.8 0.6 Unc KPpSVGVPPPApSPSYPR 0.7 0.3 0.5
Cyclin-dependent kinase inhibitor 1 CDKN1A Unc SGEQAEGpSPGGPGDSQGR 1.3 0.2 0.2 Regulator of G-protein signaling 3 isoform 6 RGS3 Unc THpSEGSLLQEPR 1.0 0.7 0.6
TBC1 domain family member 4 TBC1D4 Unc HASAPpSHVQPSDSEK 1.5 0.6 0.5 Unc HApSAPSHVQPSDSEK 1.5 0.7 0.5
SRC kinase signaling inhibitor 1 SRCIN1 Unc RGpSDELTVPR 1.3 0.7 0.6 Copper-transporting ATPase 1 ATP7A Unc pSPSYTNDSTATFIIDGM(ox)HCK 1.1 0.5 0.5
Nuclear receptor corepressor 2 isoform 1 NCOR2 Unc
SLGYHGSSYSPEGVEPVSPVSpSPpSLTHDKGLPK
1.3 0.8 0.7
Zinc finger FYVE domain-containing protein 19 ZFYVE19 Unc LPDpSDDDEDEETAIQR 0.8 0.3 0.6 Protein Jade-3 PHF16 Unc NSSTETDQQPHpSPDSSSSVHSIR 1.0 0.7 0.6 PHD finger protein 2 PHF2 Unc KGpSDDAPYpSPTAR 1.0 0.6 0.6 Autophagy-related protein 2 homolog B ATG2B Unc SYIpSPHSSPpSHTPTR 0.7 0.4 0.6 FH1/FH2 domain-containing protein 1 FHOD1 Unc pSLEGGGCPAR 1.2 0.8 0.7 Apoptosis-stimulating of p53 protein 1 PPP1R13B Unc RpSSITEPEGPGGPNIQK 0.9 0.5 0.5
103
Calmodulin-regulated spectrin-associated protein 3 isoform 1 KIAA1543 Unc DLPDGHAApSPR 1.0 0.4 0.4
Autophagy-related protein 16-1 isoform 1 ATG16L1 Unc pSVSSFPVPQDNVDTHPGSGK 1.4 0.7 0.6 WD repeat-containing protein C2orf44 isoform 1 C2orf44 Unc DSFSHpSPGAVSSLK 1.1 0.5 0.4 Myotubularin-related protein 6 MTMR6 Unc ELLHSVHPEpSPNLK 1.3 0.5 0.4 RB1-inducible coiled-coil protein 1 isoform 1 RB1CC1 Unc ASVSQTpSPQSASSPR 1.1 0.5 0.5
Dual specificity mitogen-Act protein kinase kinase 2 MAP2K2 Unc LNQPGpTPTR 1.0 0.7 0.7
Unc ELEAIFGRPVVDGEEGEPHSIpSPR 1.2 0.5 0.5
BAG family molecular chaperone regulator 3 BAG3 Unc VEVKVPPAPVPCPPPpSPGPSAVPpSSPK 1.0 0.4 0.5 Striatin-3 isoform 1 STRN3 Unc NLEQILNGGEpSPKQK 1.4 0.8 0.7
Specifically androgen-regulated gene protein isoform 1 C1orf116
Unc ANpSALTPPKPESGLTLQESNTPGLR 0.7 0.4 0.7
Unc SGVGLSSYLSTEKDApSPK 1.5 0.5 0.4
Unc
ALAQAPAPAPGPAQGPLPM(ox)KpSPAPGNVAASK
1.5 0.5 0.3
ARF GTPase-activating protein GIT1 isoform 1 GIT1 Unc HGpSGADpSDYENTQSGDPLLGLEGK 1.1 0.8 0.6 Negative elongation factor E RDBP Unc pSISADDDLQESSR 1.5 0.7 0.5
Large proline-rich protein BAT2 PRRC2A Unc KQpSSSEISLAVER 1.4 0.8 0.6 Unc ERSDSGGpSSSEPFDR 1.4 0.5 0.3 Unc ERSDpSGGSSSEPFDR 1.3 0.4 0.3
Neurobeachin-like protein 2 NBEAL2 Unc RISQVSSGEpTEYNPTEAR 1.0 0.7 0.7 FK506-binding protein 15 FKBP15 Unc RPSQEQSApSASSGQPQAPLNR 0.8 0.5 0.5 Supervillin isoform 1 SVIL Unc QAHDLpSPAAESSSTFSFSGR 0.9 0.4 0.4
Glucocorticoid receptor DNA-binding factor 1 GRLF1 Unc
SVpSSSPWLPQDGFDPSDYAEPMDAVVK
PR 1.4 0.6 0.4
Unc NEEENIpYSVPHDSTQGK 1.3 0.4 0.3 Unc NEEENIYpSVPHDSTQGK 1.3 0.3 0.2
E3 SUMO-protein ligase RanBP2 RANBP2 Unc EDALDDSVSSSSVHASPLASpSPVRK 0.9 0.5 0.6 Unc EDALDDSVSSSSVHApSPLASpSPVRK 1.2 0.4 0.3 Unc EDALDDSVSSSSVHApSPLApSSPVRK 1.0 0.3 0.3
HEAT repeat-containing protein 5A HEATR5A Unc PVTPpTSM(ox)CQGSSSGATIK 0.9 0.5 0.6 Hypothetical protein LOC54854 FAM83E Unc LSQLpSGpSpSDGDNELKK 1.2 0.7 0.7
Pleckstrin homology domain-containing family F member 1 PLEKHF1 Unc QEEAEEQGAGpSPGQPAHLAR 0.7 0.4 0.6
Structural maintenance of chromosomes protein 5 SMC5 Unc KNpSAPQLPLLQSSGPFVEGSIVR 0.7 0.4 0.7 ETS domain-containing transcription factor ERF ERF Unc TPADTGFAFPDWAYKPESpSPGSR 0.9 0.3 0.4
104
Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing subunit alpha
PIK3C2A Unc VSNLQVpSPK 1.0 0.6 0.5
Protein TANC2 TANC2 Unc PSQGLPVIQpSPPSpSPPHR 0.7 0.5 0.7 Filamin-A isoform 2 FLNA Unc RAPpSVANVGSHCDLSLK 1.2 0.7 0.7 Rho guanine nucleotide exchange factor 16 ARHGEF16 Unc (ac)AQRHSDSpSLEEK 0.8 0.6 0.6 Cytoplasmic dynein 1 light intermediate chain 1 DYNC1LI1 Unc KPVTVSPTTPTpSPTEGEAS 1.0 0.7 0.7 Histone deacetylase 7 isoform a HDAC7 Unc AQpSSPAAPASLSAPEPASQAR 0.8 0.4 0.5 Paxillin isoform 1 PXN Unc QKpSAEPpSPTVM(ox)STSLGSNLSELDR 1.0 0.5 0.5 ATPase WRNIP1 isoform 1 WRNIP1 Unc RPAAAAAAGpSApSPR 1.1 0.9 0.6
Cytochrome b reductase 1 isoform 1 CYBRD1 Unc
GpSM(ox)PAYSGNNM(ox)DKSDSELNSEVAAR
0.9 0.5 0.6
Oxysterol-binding protein-related protein 1 isoform B OSBPL1A Unc pSFEEEGEHLGSR 1.4 0.3 0.2 DNA topoisomerase 2-beta TOP2B Unc KApSGpSENEGDYNPGR 1.0 0.4 0.4 Enhancer of mRNA-decapping protein 3 EDC3 Unc SQDVAVpSPQQQQCSK 1.1 0.6 0.5 GAS2-like protein 1 isoform a GAS2L1 Unc RpYSGDSDSpSASSAQSGPLGTR 1.3 0.8 0.6
Ladinin-1 LAD1 Unc IPSKEEEADMpSSPTQR 1.3 0.4 0.3 Unc IPSKEEEADM(ox)SpSPTQR 1.4 0.3 0.3
Nucleobindin-1 precursor NUCB1 Unc AQRLSQEpTEALGR 1.1 0.9 0.7 Protein NDRG1 NDRG1 Unc SHpTSEGAHLDITPNSGAAGNSAGPK 1.0 0.5 0.6 Target of Myb protein 1 isoform 2 TOM1 Unc AADRLPNLSpSPSAEGPPGPPSGPAPR 0.8 0.4 0.5 Poliovirus receptor isoform alpha PVR Unc ENpSSSQDPQTEGTR 1.3 0.8 0.5 Protein MICAL-3 isoform 1 MICAL3 Unc KTpSQSEEEEAPR 1.3 0.6 0.4
Nuclear pore complex protein Nup98-Nup96 isoform 1 NUP98
Unc DSENLApSPSEYPENGER 1.3 0.5 0.5
Unc
NLNNSNLFpSPVNRDSENLASPpSEYPENGER
1.3 0.5 0.4
Mitogen-Act protein kinase kinase kinase 7 isoform B MAP3K7 Unc pSIQDLTVTGTEPGQVSSR 0.9 0.5 0.6
Regulatory-associated protein of mTOR isoform 1 RPTOR Unc VLDTSSLTQSAPApSPTNK 1.2 0.8 0.6 C-myc promoter-binding protein isoform 1 DENND4A Unc pSISTSGPLDKEDTGR 1.0 0.9 0.6 LIM domain only protein 7 isoform 2 LMO7 Unc SApSVNKEPVSLPGIM(ox)R 1.5 0.9 0.6
Serine/threonine-protein kinase Nek9 NEK9
Unc VASEAPLEHKPQVEASpSPR 1.1 0.6 0.6
Unc
HCDSINSDFGSESGGCGDSpSPGPSASQGPR
1.1 0.5 0.5
Cytospin-A SPECC1L Unc KGpSpSGNApSEVSVACLTER 1.2 0.6 0.6 Unc RSpSTSSEPTPTVK 1.2 0.6 0.5 Unc HpSISGPISTSKPLTALSDK 0.9 0.4 0.5
105
Unc RpSSTSSEPTPTVK 1.1 0.3 0.3
Ankycorbin isoform d RAI14 Unc AEISpSIRENK 1.0 0.5 0.5 Unc AEIpSSIRENK 1.3 0.5 0.5
Rap1 GTPase-activating protein 1 isoform a RAP1GAP Unc AAGISLIVPGKSPpTR 1.2 0.7 0.5 Unc RSpSAIGIENIQEVQEK 1.4 0.7 0.5 Unc pSQSM(ox)DAM(ox)GLSNK 1.3 0.6 0.5
FCH domain only protein 2 isoform a FCHO2 Unc VSIGNIpTLSPAISRHpSPVQM(ox)NR 0.8 0.5 0.6 E3 ubiquitin-protein ligase ZNRF2 ZNRF2 Unc AYpSGSDLPSSSSGGANGTAGGGGGAR 1.5 0.4 0.3
Pleckstrin homology domain-containing family A member 7 PLEKHA7 Unc KVTpSPLQpSPTK 1.2 0.7 0.7
Unc KVTpSPLQSPpTK 1.2 0.7 0.6
Transcription factor EB TFEB Unc FAAHIpSPAQGpSPKPPPAApSPGVR 0.8 0.5 0.6
Nuclear pore complex protein Nup153 NUP153 Unc RIPSIVpSSPLNpSPLDR 1.5 0.7 0.5 Unc VQMTpSPSSTGSPM(ox)FK 0.9 0.2 0.4
Rho guanine nucleotide exchange factor 2 isoform 1 ARHGEF2 Unc LQDSSDPDTGSEEEGSSRLpSPPHpSPR 1.0 0.6 0.5 Serine/threonine-protein kinase MARK2 isoform d MARK2 Unc DQQNLPYGVTPASPSGHpSQGR 0.9 0.6 0.6 Coiled-coil domain-containing protein 120 isoform 1 CCDC120 Unc RNpSVApSPTSPTR 1.4 0.8 0.5 Zinc finger protein 828 ZNF828 Unc KTpSPASLDFPESQK 0.9 0.6 0.6
Perilipin-3 isoform 1 PLIN3 Unc ELVSSKVpSGAQEM(ox)VSSAK 0.8 0.3 0.4 Unc ELVSpSKVSGAQEMVSSAK 0.9 0.3 0.4
Serine/threonine-protein phosphatase 1 regulatory subunit 10 PPP1R10 Unc VLpSPTAAKPSPFEGK 1.0 0.7 0.6
Ataxin-2-like protein isoform C ATXN2L Unc GPPQpSPVFEGVYNNSR 0.8 0.6 0.7
Prelamin-A/C isoform 1 precursor LMNA Unc GRASpSHpSSQTQGGGSVTK 1.2 1.6 0.6 Unc ApSSHpSSQTQGGGSVTK 1.1 0.6 0.6 Unc ASSHpSpSQTQGGGSVTK 1.1 0.9 0.6
Lamin-B2 LMNB2 Unc LKLSPSPpSSR 1.0 0.9 0.7 Myosin-XVIIIa isoform a MYO18A Unc SRDESASETSTPpSEHSAAPSPQVEVR 1.0 0.7 0.7
Myosin-XVIIIa isoform a MYO18A
Unc SRDESASETSTPSEHSAAPpSPQVEVR 0.9 0.7 0.6
Unc
RVpSpSSSELDLPSGDHCEAGLLQLDVPLLR
1.3 0.6 0.5
Alpha-taxilin TXLNA Unc RPEGPGAQAPpSSPR 0.8 0.3 0.4
Protein Shroom1 isoform 1 SHROOM1 Unc pSASLSHPGGEGEPAR 1.3 0.6 0.5 Unc SApSLSHPGGEGEPAR 1.3 0.5 0.3
Leucine-rich repeat-containing protein 16A isoform 1 LRRC16A Unc RpSSGFISELPSEEGK 1.1 0.6 0.6 Microtubule-associated protein tau isoform 6 MAPT Unc SPVVSGDTpSPR 1.2 0.7 0.6
Src substrate cortactin isoform c CTTN Unc LPSpSPVYEDAASFK 1.0 0.6 0.6 Unc AKpTQTPPVpSPAPQPTEER 0.9 0.3 0.3
106
Serine/threonine-protein kinase WNK1 isoform 4 WNK1 Unc DVDDGSGSPHpSPHQLSSK 1.3 0.7 0.5 Condensin-2 complex subunit H2 isoform 3 NCAPH2 Unc EpSRSPQQSAALPR 0.9 0.4 0.4 Allograft inflammatory factor 1-like isoform 3 AIF1L Unc ANEpSSPKPVGPPPER 0.9 0.8 0.7 Hypothetical protein LOC9847 KIAA0528 Unc SQpSESpSDEVTELDLSHGKK 1.4 0.9 0.7
Calpastatin isoform m CAST Unc
ELLAKPIGPDDAIDALSSDFTCGpSPTAAGK
1.0 0.5 0.6
Band 4.1-like protein 1 isoform a EPB41L1 Unc LPSSPApSPSPK 0.9 0.6 0.6 Unc RLPpSpSPASPSPK 0.9 0.4 0.4
absent in melanoma 1-like protein AIM1L Unc EVVKGPGAPAASpSPTQK 1.0 0.5 0.6
Clathrin interactor 1 isoform 1 CLINT1 Unc
TIDLGAAAHYTGDKApSPDQNASTHTPQSSVK
0.8 0.5 0.6
D-tyrosyl-tRNA(Tyr) deacylase 1 DTD1 Unc SASpSGAEGDVSSEREP 0.9 0.6 0.7 PREDICTED: putative uncharacterized serine/threonine-protein kinase SgK110-like
LOC100130827
Unc RApSETPEDGDPEEDTATALQR 1.3 0.6 0.5
PREDICTED: e3 ubiquitin-protein ligase UBR5-like isoform 1, partial
LOC730429 Unc RIpSQSQPVR 1.3 0.7 0.6
Nuclear fragile X mental retardation-interacting protein 2 NUFIP2 Unc
ADTSSQGALVFLSKDYEIESQNPLApSPTNTLLGSAK
1.2 0.5 0.4
Cytoplasmic dynein 1 heavy chain 1 DYNC1H1 Unc TDpSTSDGRPAWMR 1.4 0.7 0.5 Nuclear pore complex protein Nup214 NUP214 Unc TPpSIQPSLLPHAAPFAK 0.9 0.3 0.4
Pleckstrin homology domain-containing family A member 6 PLEKHA6 Unc SIHEVDIpSNLEAALR 1.4 1.1 0.6
TSC22 domain family protein 3 isoform 1 TSC22D3 Unc GSSGENNNPGSPpTVSNFR 1.3 0.8 0.7 Unc GSSGENNNPGpSPTVSNFR 1.2 0.5 0.5
Rho guanine nucleotide exchange factor 11 isoform 2 ARHGEF11 Unc SLGGESSGGpTpTPVGSFHTEAAR 1.3 0.6 0.7
Protein lunapark KIAA1715
Unc
NLSPpTPASPNQGPPPQVPVSPGPPKDSSAPGGPPER
0.7 0.4 0.6
Unc
NLSPTPASPNQGPPPQVPVpSPGPPKDSSAPGGPPER
0.7 0.3 0.3
Ankyrin repeat domain-containing protein 17 isoform a ANKRD17 Unc EHYPVSSPSpSPpSPPAQPGGVSR 0.7 0.4 0.6
Insulin receptor substrate 2 IRS2
Unc RVpSGDAAQDLDR 1.5 1.0 0.6 Unc SSEGGVGVGPGGGDEPPTpSPR 1.2 0.4 0.4
Unc PVSVAGpSPLpSPGPVRAPLSR 1.2 0.3 0.3
Plectin isoform 1 PLEC Unc SSpSVGSSSSYPISPAVSR 1.2 0.6 0.6
107
Fatty acid synthase FASN Unc ADEASELACPpTPKEDGLAQQQTQLNLR 1.5 0.3 0.3 Peptidyl-prolyl cis-trans isomerase G PPIG Unc ADRDQSPFpSK 0.9 0.8 0.4 Protein Shroom2 SHROOM2 Unc AQSPGpSPLHAR 1.4 0.6 0.5
Transcription factor jun-B JUNB Unc SRDApTPPVpSPINM(ox)EDQER 1.2 0.9 0.7 Unc SRDApTPPVpSPINMEDQER 1.3 0.8 0.7
Peroxisome biogenesis factor 1 PEX1 Unc pSQSGEDESM(ox)NQPGPIK 1.0 0.6 0.6 Ras GTPase-activating-like protein IQGAP1 IQGAP1 Unc pSVKEDSNLTLQEK 1.0 0.6 0.6 Small glutamine-rich tetratricopeptide repeat-containing protein alpha
SGTA Unc pSRTPSASNDDQQE 1.1 0.2 0.3
Zyxin ZYX Unc pSPGAPGPLTLK 0.9 0.5 0.6 WD repeat-containing protein 44 isoform 1 WDR44 Unc YNTEGRVpSPSPpSQESLSSSK 0.9 0.6 0.6
Protein scribble homolog isoform a SCRIB Unc QSPApSPPPLGGGAPVR 0.9 0.5 0.6 Unc RSEACPCQPDSGpSPLPAEEEK 0.9 0.6 0.6
Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1
ASAP1 Unc TLpSDPPpSPLPHGPPNK 0.9 0.5 0.5
Synaptotagmin-like protein 2 isoform d SYTL2 Unc RNpSLTASLDK 1.3 0.9 0.6
coiled-coil domain-containing protein 6 CCDC6 Unc LDQPVSAPPpSPR 0.8 0.4 0.5 Unc LDQPVpSAPPpSPR 0.8 0.4 0.5
7SK snRNA methylphosphate capping enzyme isoform A MEPCE Unc TLNAETPKpSSPLPAK 0.9 0.5 0.6
Death-associated protein 1 DAP Unc (ac)SpSPPEGKLETK 1.3 0.5 0.3
Eukaryotic translation initiation factor 4E-binding protein 1 EIF4EBP1 Unc
RVVLGDGVQLPPGDYSTpTPGGTLFSTpTPGGTR
0.9 0.6 0.6
Eukaryotic translation initiation factor 4E-binding protein 1 EIF4EBP1 Unc FLM(ox)ECRNpSPVTK 1.0 0.5 0.4
Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1
GBF1 Unc AASSSSPGpSPVASSPSR 1.4 0.3 0.4
Ribosomal protein S6 kinase alpha-3 RPS6KA3 Unc NQpSPVLEPVGR 0.9 0.6 0.7 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 SLC9A3R1 Unc EALAEAALEpSPRPALVR 1.1 0.6 0.4 Periphilin-1 isoform 1 PPHLN1 Unc DTpSPSSGSAVSSSK 1.1 0.7 0.6 Myeloid leukemia factor 2 MLF2 Unc LAIQGPEDSPpSRQpSR 0.8 0.5 0.6
Insulin receptor substrate 1 IRS1 Unc
ApSSDGEGTM(ox)SRPASVDGSPVpSPSTNR
1.4 0.5 0.4
Annexin A2 isoform 1 ANXA2 Unc LSLEGDHSpTPPSAYGSVK 0.9 0.5 0.7 G patch domain-containing protein 8 GPATCH8 Unc KPpSVSEEVQATPNK 1.4 0.5 0.3 Niban-like protein 1 isoform 1 FAM129B Unc AAPEApSSPPASPLQHLLPGK 0.7 0.3 0.4 Actin-binding LIM protein 1 isoform a ABLIM1 Unc pTLSPTPSAEGYQDVR 0.8 0.5 0.7 Chromodomain-helicase-DNA-binding protein 4 CHD4 Unc MSQPGpSPSPK 1.0 0.6 0.4
108
NGFI-A-binding protein 2 NAB2 Unc APpSPTAEQPPGGGDSAR 0.7 0.3 0.4
Integrin beta-4 isoform 3 precursor ITGB4
Unc DYSTLTpSVSpSHDSR 1.3 0.7 0.5 Unc M(ox)DFAFPGSpTNpSLHR 1.5 0.4 0.3 Unc M(ox)DFAFPGpSTNpSLHR 1.5 0.4 0.3
Protein KHNYN KHNYN Unc PApSPDRFAVSAEAENK 1.0 0.6 0.3
Receptor tyrosine-protein kinase erbB-3 isoform 1 precursor ERBB3 Unc REpSGPGIAPGPEPHGLTNK 0.9 0.6 0.7
TRAF2 and NCK-interacting protein kinase isoform 1 TNIK Unc ANpSKpSEGSPVLPHEPAK 1.4 0.5 0.4
Glucocorticoid-induced transcript 1 protein GLCCI1 Unc pSIDTQTPSVQER 0.8 0.6 0.7
Protein Smaug homolog 2 SAMD4B Unc
AAFTTPDHAPLpSPQSSVASSGSEQTEEQGSSR
1.0 0.6 0.6
SH3 and PX domain-containing protein 2A SH3PXD2A Unc EAEEGPTGASESQDpSPR 1.0 0.5 0.6
Golgi SNAP receptor complex member 1 isoform 2 GOSR1 Unc RDSSDTpTPLLNGSSQDR 1.3 0.7 0.6 Unc RDSSDpTTPLLNGSSQDR 1.4 0.7 0.5
CLIP-associating protein 2 CLASP2 Unc NTGNGTQSSM(ox)GpSPLTRPTPR 0.9 0.5 0.7 Sodium-dependent phosphate transporter 2 SLC20A2 Unc NNpSYTCYTAAICGLPVHATFR 1.4 0.8 0.6 Rapamycin-insensitive companion of mTOR RICTOR Unc pSNSVSLVPPGSSHTLPR 0.7 0.4 0.6
Neuroblast differentiation-associated protein AHNAK isoform 1 AHNAK
Unc LPpSGSGAASPTGSAVDIR 1.1 0.7 0.6
Unc ASLGSLEGEAEAEASpSPK 1.3 0.6 0.5
Unc FKAEAPLPpSPK 1.4 0.1 0.1
Rhotekin isoform a RTKN Unc RPpSDSGPPAER 1.0 0.6 0.6 Unc LATKLSpSpSLGR 1.0 0.3 0.4
Hypothetical protein LOC57613 KIAA1467 Unc
SPLGEAPEPDpSDAEVAEAAKPHLSEVTTEGYPSEPLGGLEQK
1.2 0.1 0.0
Absent in melanoma 1 protein AIM1 Unc SpTDSPGADAELPESAAR 1.1 0.3 0.3
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 isoform a PFKFB2 Unc RNpSFTPLSSSNTIR 1.4 0.6 0.4
Tensin-1 TNS1 Unc AQFSVAGVHTVPGpSPQAR 1.0 0.7 0.7 ATP-dependent RNA helicase DHX29 DHX29 Unc FQSPQIQATIpSPPLQPK 0.7 0.6 0.6 B-cell CLL/lymphoma 9 protein BCL9 Unc AVpTPVSQGSNSSSADPK 1.0 0.7 0.6
Sister chromatid cohesion protein PDS5 homolog B PDS5B Unc M(ox)ETVSNASSSSNPSpSPGR 0.8 0.6 0.7
Unc AEpSPESSAIESTQSTPQK 0.7 0.4 0.6
Actin-binding LIM protein 3 ABLIM3 Unc RTpSETSIpSPPGSSIGSPNR 1.5 0.9 0.5 Forkhead box protein K1 FOXK1 Unc SGGLQTPECLpSREGpSPIPHDPEFGSK 1.0 0.4 0.5
109
Hypothetical protein LOC9870 KIAA0317 Unc RPpSTAVDEEDEDpSPSECHTPEK 1.1 0.7 0.7 Microtubule-associated protein 2 isoform 1 MAP2 Unc VDHGAEIITQpSPGR 0.8 0.6 0.6 Regulator of microtubule dynamics protein 3 FAM82A2 Unc SQpSLPNSLDYTQTSDPGR 1.0 0.6 0.7 Zinc finger protein 446 ZNF446 Unc TEEPLGpSPHPSGTVESPGEGPQDTR 0.8 0.6 0.7
Bromodomain adjacent to zinc finger domain protein 2A BAZ2A Unc AGDPGEM(ox)PQpSPTGLGQPK 1.1 0.7 0.6
Vesicle-trafficking protein SEC22b SEC22B Unc NLGpSINTELQDVQR 1.0 0.6 0.6 Unc RNLGSINpTELQDVQR 0.9 0.6 0.5
Eukaryotic elongation factor 2 kinase EEF2K Unc KYEpSDEDpSLGSSGR 1.3 0.6 0.4 Bcl2 antagonist of cell death BAD Act HpSSYPAGTEDDEGM(ox)GEEPSPFR 1.8 0.3 0.2 Filamin A-interacting protein 1-like isoform 1 FILIP1L Act RIpSDPQVFSK 1.8 0.7 0.4
Melanophilin isoform 2 MLPH Act ASpSESQGLGAGVR 3.2 0.2 0.1
Repressor of RNA polymerase III transcription MAF1 homolog MAF1 Act LpSKSQGGEEEGPLSDK 2.3 0.8 0.2
Act LSKpSQGGEEEGPLSDK 2.6 0.6 0.2
182 kDa tankyrase-1-binding protein TNKS1BP1 Act HNGSLpSPGLEAR 1.5 0.7 0.5 Act NRpSAEEGELAESK 1.9 0.8 0.4
Hypothetical protein LOC91748 C14orf43 Act RApSQEANLLTLAQK 2.3 1.2 0.6 Regulator of G-protein signaling 3 isoform 6 RGS3 Act KM(ox)pSGADTVGDDDEASR 2.2 0.4 0.2 Nucleoprotein TPR TPR Act TDGFAEAIHpSPQVAGVPR 2.0 1.0 0.5 Zinc finger CCCH domain-containing protein 13 ZC3H13 Act KTpSAVSpSPLLDQQR 2.1 1.4 0.7
interferon regulatory factor 2-binding protein 2 isoform A IRF2BP2 Act KPpSPEPEGEVGPPK 1.8 0.5 0.3
PHD finger protein 2 PHF2 Act RPpSApSSPNNNTAAK 1.7 0.7 0.4 Act RPpSASpSPNNNTAAK 1.6 0.6 0.4
Dedicator of cytokinesis protein 5 DOCK5 Act LSPFHGSSPPQSTPLpSPPPLpTPK 1.5 0.9 0.6
Serine/arginine repetitive matrix protein 2 SRRM2 Act pSGSSQELDVKPSASPQER 1.6 1.1 0.7 Act TPAAAAAM(ox)NLApSPR 1.8 0.8 0.5
Serine/threonine-protein kinase D2 isoform A PRKD2 Act RLpSpSTSLASGHSVR 2.1 0.4 0.2 Probable E3 ubiquitin-protein ligase HERC1 HERC1 Act RVpSTDLPEGQDVYTAACNSVIHR 17.8 6.5 0.4 Serine/threonine-protein kinase 10 STK10 Act LSEEAECPNPSpTPSK 1.5 0.9 0.6
Pleckstrin homology domain-containing family F member 2 PLEKHF2 Act SDpSYSQSLK 4.3 0.5 0.1
Phosphatidylinositol 4-kinase type 2-alpha PI4K2A Act SpSSESYTQSFQSR 1.9 0.5 0.2
Protein NDRG3 isoform a NDRG3 Act pTHSTSSSLGSGESPFSR 1.9 1.0 0.6 Act THSTpSSSLGSGESPFSR 1.8 0.8 0.5 Act THpSTSSSLGSGESPFSR 2.1 0.8 0.4
Specifically androgen-regulated gene protein isoform 1 C1orf116 Act SpTTQASSHNPGEPGR 1.6 0.7 0.5
110
Act SGVGLSSYLpSTEKDASPK 1.7 0.6 0.4
Catenin delta-1 isoform 1ABC CTNND1 Act SLDNNpYSTPNER 1.8 0.5 0.3 Act GSLASLDpSLRK 2.5 0.2 0.1
Tyrosine-protein kinase BAZ1B BAZ1B Act LAEDEGDpSEPEAVGQSR 1.6 1.1 0.7
Catenin beta-1 CTNNB1 Act RpTSMGGTQQQFVEGVR 1.7 1.3 0.7 Act RTpSM(ox)GGTQQQFVEGVR 1.9 1.1 0.5 Act RTSMGGpTQQQFVEGVR 2.0 1.1 0.5
Septin-7 isoform 1 SEPT7 Act ILEQQNSSRpTLEK 2.2 1.1 0.6
Probable ATP-dependent RNA helicase DDX17 isoform 3 DDX17 Act TTpSSANNPNLMYQDECDRR 10.1 0.8 0.1
Proline-rich AKT1 substrate 1 AKT1S1 Act LNTpSDFQK 2.0 0.9 0.5 Act LNpTSDFQK 1.9 0.1 0.0
Glucocorticoid receptor DNA-binding factor 1 GRLF1 Act NQKNpSLSDPNIDR 2.9 0.3 0.1 Splicing factor, arginine/serine-rich 18 SFRS18 Act pSKFDSDEEEEDTENVEAASSGK 1.6 0.6 0.5
FAM83H FAM83H Act RLpSLGQGDSTEAATEER 1.8 0.9 0.5 Act LpSSATANALYSSNLR 4.0 1.0 0.4
LIM and calponin homology domains-containing protein 1 isoform a LIMCH1 Act pSVSQDLIKK 2.3 0.9 0.4
Paxillin isoform 1 PXN Act TSSVSNPQDSVGpSPCSR 1.8 1.1 0.6
40S ribosomal protein S6 RPS6 Act LSpSLRApSTSK 2.6 0.4 0.2 Act RLpSpSLR 2.6 0.4 0.1
Autism susceptibility gene 2 protein isoform 1 AUTS2 Act TPVVESARPNpSTSSR 2.0 1.2 0.4 ATPase WRNIP1 isoform 1 WRNIP1 Act RLSEpSSALK 1.6 0.7 0.5 Syntaxin-binding protein 5 isoform b STXBP5 Act SpSSVTpSIDKESR 1.7 1.0 0.6 Protein PAT1 homolog 1 PATL1 Act RSTpSPIIGpSPPVR 1.5 0.6 0.4 Sperm-specific antigen 2 isoform 1 SSFA2 Act IGpSM(ox)SSVTSNK 5.7 0.7 0.1
Pleckstrin homology-like domain family B member 2 isoform a PHLDB2 Act KSpSISSISGR 1.9 1.1 0.6
Act KSpSISpSISGR 2.6 1.1 0.5
DNA topoisomerase 2-alpha TOP2A Act KPpSpTpSDDpSDSNFEK 2.9 1.8 0.7 Calmin CLMN Act SpSESDHFSYVQLR 2.2 1.4 0.7 Hermansky-Pudlak syndrome 3 protein HPS3 Act pSHSEMKLVCGFILEPR 129.6 1.6 0.0
Unconventional prefoldin RPB5 interactor isoform a C19orf2 Act KNpSTGSGHSAQELPTIR 2.1 1.0 0.5
Ladinin-1 LAD1 Act NLpSSTTDDEAPR 2.5 0.8 0.3 Act NLSSpTTDDEAPR 2.5 0.7 0.3
Ladinin-1 LAD1 Act NLSpSTTDDEAPR 2.7 0.6 0.2 Act IPSKEEEADM(ox)SSPpTQR 1.8 0.3 0.2
Rho GTPase-activating protein 21 ARHGAP21 Act KDSpSSEVFSDAAK 1.6 0.4 0.2
111
Protein NDRG1 NDRG1 Act pSHTSEGAHLDITPNSGAAGNSAGPK 2.1 0.6 0.4 Act pSRTApSGpSSVpTSLDGTR 2.0 0.3 0.1 Act pTASGSSVTSLDGTR 2.0 0.2 0.1
Mitogen-Act protein kinase 1 MAPK1 Act VADPDHDHTGFLTEpYVATR 1.7 1.2 0.7 Act VADPDHDHTGFLpTEpYVATR 9.5 3.3 0.4
Protein SON isoform F SON Act SFpSIpSPSRR 2.6 1.1 0.4 Act pSFpSIpSPSRR 2.6 1.1 0.4
Leucine-rich repeat flightless-interacting protein 1 isoform 3 LRRFIP1 Act RGSGDTSIpSIDTEASIR 7.1 1.2 0.2
Nuclear pore complex protein Nup98-Nup96 isoform 1 NUP98 Act NLNNSNLFpSPVNR 1.6 0.9 0.6
Programmed cell death protein 4 isoform 1 PDCD4 Act FVpSEGDGGR 2.4 0.7 0.3 Act DSGRGDpSVSDSGSDALR 3.4 0.5 0.1
Rho GTPase-activating protein 32 isoform 1 ARHGAP32 Act SAKpSEESLTSLHAVDGDSK 3.1 1.1 0.4
Protein phosphatase 1 regulatory subunit 12A isoform a PPP1R12A Act LApSTSDIEEKENR 8.0 0.7 0.1
LIM domain only protein 7 isoform 2 LMO7 Act RGEpSLDNLDpSPR 2.5 1.5 0.6 Hypothetical protein LOC254427 C10orf47 Act SRpSFTLDDESLK 2.2 0.9 0.4
Tyrosine-protein phosphatase non-receptor type 3 isoform 1 PTPN3 Act pSLSVEHLETK 2.3 0.6 0.3
Cytospin-A SPECC1L Act KGpSSGNASEVSVACLTER 2.0 0.8 0.4
Ankycorbin isoform d RAI14 Act KAPPPPIpSPTQLSDVSpSPR 2.1 1.1 0.5 Act pSITSpTPLpSGK 2.1 0.9 0.5
Rap1 GTPase-activating protein 1 isoform a RAP1GAP Act RpSSAIGIENIQEVQEK 1.5 0.8 0.6 E3 ubiquitin-protein ligase ZNRF2 ZNRF2 Act pSLGGAVGSVASGAR 1.9 0.9 0.5 Cytosolic phospholipase A2 PLA2G4A Act CpSVSLSNVEAR 1.8 0.5 0.2 CTTNBP2 N-terminal-like protein CTTNBP2NL Act VSSPLSPLpSPGIKpSPTIPR 1.8 0.3 0.2 Nuclear pore complex protein Nup153 NUP153 Act EGSVLDILKpSPGFASPK 3.4 1.0 0.3 Serine/threonine-protein kinase MARK2 isoform d MARK2 Act GRNpSATSADEQPHIGNYR 1.5 0.7 0.5
Ubiquitin carboxyl-terminal hydrolase 24 USP24 Act
TIpSAQDTLAYATALLNEKEQSGSSNGSESSPANENGDR
1.8 0.6 0.4
Palladin isoform 1 PALLD Act IApSDEEIQGTK 2.2 0.3 0.2 WD repeat-containing protein 26 isoform a WDR26 Act RLpSQSDEDVIR 1.5 0.8 0.5 Hypothetical protein LOC126353 C19orf21 Act RALSpSDSILpSPAPDAR 1.7 1.0 0.6 PHD finger protein 6 isoform 1 PHF6 Act KpTAHNSEADLEESFNEHELEPpSSPK 1.5 0.3 0.2
Rab3 GTPase-activating protein catalytic subunit isoform 1 RAB3GAP1 Act KTSASDVpTNIYPGDAGK 4.3 0.4 0.1
Act KTpSASDVTNIYPGDAGK 4.3 0.2 0.0
Rab11 family-interacting protein 1 isoform 3 RAB11FIP1 Act RSpSLLSLM(ox)TGK 1.5 0.6 0.4
112
Kinesin-like protein KIF21A isoform 1 KIF21A Act KLSSSDAPAQDTGSpSAAAVETDASR 3.6 0.4 0.1 Probable E3 ubiquitin-protein ligase MYCBP2 MYCBP2 Act pSKSDSYTLDPDTLR 1.6 0.4 0.3
Zinc finger protein 185 isoform 3 ZNF185 Act REpSCGSSVLTDFEGK 1.9 0.9 0.5 Act RESCGpSSVLTDFEGK 1.7 0.8 0.4
Epidermal growth factor receptor isoform a precursor EGFR
Act NGLQSCPIKEDpSFLQR 2.2 1.2 0.5
Act GSHQISLDNPDpYQQDFFPK 3.8 0.4 0.1
Act GSTAENAEpYLR 4.3 0.3 0.1
Phosphofurin acidic cluster sorting protein 1 PACS1 Act TNpSSDSERSPDLGHSTQIPR 2.3 1.3 0.6
Family with sequence similarity 64, member A isoform 2 FAM64A Act pSLQHQEQLEDSK 3.6 1.3 0.2
PREDICTED: afadin-like isoform 1, partial LOC10050581
8 Act LFpSQGQDVSNK 4.8 0.2 0.0
PREDICTED: e3 ubiquitin-protein ligase UBR5-like isoform 1, partial
LOC730429 Act RISQpSQPVR 1.5 0.3 0.2
Protein kinase C delta type PRKCD Act RSDpSASSEPVGIYQGFEK 2.0 0.7 0.3 CLIP-associating protein 1 isoform 1 CLASP1 Act RQpSSGSATNVASTPDNR 1.5 0.7 0.5 B-cell CLL/lymphoma 9-like protein BCL9L Act SVpSVDSGEQR 1.8 1.4 0.6 Ephrin type-A receptor 2 precursor EPHA2 Act VSIRLPpSpTSGSEGVPFR 1.9 0.5 0.3
Ankyrin-3 isoform 1 ANK3 Act RQpSFASLALR 1.7 1.1 0.6 Act RQSFApSLALR 1.8 0.7 0.4
Serine/threonine-protein kinase SRPK2 isoform a SRPK2 Act TVpSASpSTGDLPK 1.6 0.5 0.3 Cytoplasmic dynein 1 heavy chain 1 DYNC1H1 Act pTDSTSDGRPAWMR 1.6 0.7 0.4 Enhanced at puberty protein 1 C14orf4 Act RPGpSVSSTDQER 1.7 0.6 0.4 Zinc finger RNA-binding protein ZFR Act RDpSDGVDGFEAEGK 2.0 0.9 0.4
Synergin gamma isoform 1 SYNRG Act pSLSLGDKEISR 1.9 0.9 0.4 Act SLpSLGDKEISR 1.9 0.8 0.4
ATP-citrate synthase isoform 1 ACLY Act TApSFSESR 1.9 0.8 0.4
Insulin receptor substrate 2 IRS2 Act pTASEGDGGAAAGAAAAGAR 2.1 0.7 0.3 Act TApSEGDGGAAAGAAAAGAR 1.9 0.5 0.3 Act KSpSEGGVGVGPGGGDEPPpTSPR 1.9 0.2 0.1
Rho-associated protein kinase 2 ROCK2 Act IQQNQpSIR 1.6 0.8 0.5 Stathmin isoform a STMN1 Act ASGQAFELILpSPR 3.0 0.7 0.2
Heat shock protein beta-1 HSPB1 Act QLSpSGVSEIR 1.6 0.9 0.6 Act QLpSSGVSEIR 1.6 0.9 0.6
Nuclear cap-binding protein subunit 1 NCBP1 Act KTpSDANETEDHLESLICK 2.2 0.3 0.2 Small glutamine-rich tetratricopeptide repeat-containing protein alpha
SGTA Act SRTPpSASNDDQQE 1.8 0.6 0.3
Transgelin-2 TAGLN2 Act NFpSDNQLQEGK 1.8 1.0 0.6
113
Serine/threonine-protein kinase ULK1 ULK1 Act NLQpSPTQFQTPR 1.6 0.5 0.4 Act NPLPPILGpSPTK 1.6 0.6 0.4
Eukaryotic translation initiation factor 4E-binding protein 2 EIF4EBP2 Act (ac)SpSSAGSGHQPSQSR 1.7 0.7 0.5
Eukaryotic translation initiation factor 4B EIF4B Act SRTGpSEpSSQTGTSTTSSR 2.1 0.6 0.2 Act pTGSESSQTGTSTTSSR 2.6 0.4 0.0
Insulin receptor substrate 1 insulin receptor substrate 1
IRS1 IRS1
Act THpSAGTpSPTITHQK 1.7 0.9 0.6 Act KGpSGDYM(ox)PM(ox)pSPK 2.2 0.2 0.1
Nucleolar RNA helicase 2 DDX21 Act KAEPSEVDM(ox)NpSPK 1.7 1.0 0.6 DNA-directed RNA polymerase I subunit RPA43 TWISTNB Act KHpSEEAEFTPPLK 1.5 0.5 0.4
WASH complex subunit FAM21A FAM21A Act pSRPTpSFADELAAR 1.9 0.4 0.2 Act pSRPpTSFADELAAR 2.0 0.4 0.2
Integrin beta-4 isoform 3 precursor ITGB4 Act SPSGSQRPpSVSDDTEHLVNGR 2.3 1.2 0.5
Catenin alpha-1 CTNNA1 Act pSRTSVQTEDDQLIAGQSAR 2.2 0.9 0.4 Act SRTpSVQTEDDQLIAGQSAR 2.2 0.7 0.3
Protein enabled homolog isoform a ENAH Act TNTM(ox)NGpSKSPVISR 1.8 1.0 0.4
Cullin-4A isoform 1 CUL4A Act KGpSFSALVGR 2.0 0.6 0.3
KH domain-containing, RNA-binding, signal transduction-associated protein 1
KHDRBS1 Act pSGSM(ox)DPSGAHPSVR 3.2 0.9 0.7
Act SGpSMDPSGAHPSVR 1.8 0.9 0.5
PALM2-AKAP2 protein isoform 1 PALM2-AKAP2
Act QVLQSpTQSPR 2.2 0.8 0.3
Neuroblast differentiation-associated protein AHNAK isoform 1 AHNAK
Act ASLGpSLEGEAEAEApSSPKGK 1.6 0.8 0.5
Act ISM(ox)QDVDLSLGpSPK 1.7 1.0 0.5
Act VSM(ox)PDVELNLKpSPK 2.8 0.6 0.2
Act MYFPDVEFDIKpSPK 2.6 0.5 0.2
Act LKpSEDGVEGDLGETQSR 3.4 0.3 0.0
Zinc finger protein 2 isoform a ZNF2 Act MGTEKQSPpSGEpTR 13.1 0.9 0.1 Act MGTEKQpSPSGEpTR 21.7 0.2 0.0
Absent in melanoma 1 protein AIM1 Act LLEKEDpSEAADSK 2.7 0.5 0.1 Tensin-3 TNS3 Act KLpSLGQYDNDAGGQLPFSK 1.8 1.1 0.7 Nuclear-interacting partner of ALK ZC3HC1 Act LCpSSSSSDTSSR 2.4 0.3 0.1
Signal-induced proliferation-associated 1-like protein 1 SIPA1L1 Act pSKSETGDSSIFR 1.9 0.9 0.4
114
Apoptotic chromatin condensation inducer in the nucleus isoform 1 ACIN1 Act RLpSQPESAEK 1.8 0.7 0.7
Actin-binding LIM protein 3 ABLIM3 Act RFpSpSGGEEDDFDR 2.0 0.6 0.3 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 1 isoform 1
AGAP1 Act NNpSSGRVPTII 1.5 0.9 0.6
E3 ubiquitin-protein ligase UBR4 UBR4 Act pTGSTSSKEDDYESDAATIVQK 1.6 0.3 0.2 Act TGpSTSSKEDDYESDAATIVQK 1.6 0.3 0.2
E3 ubiquitin-protein ligase UBR4 UBR4 Act TGSTSSKEDDpYESDAATIVQK 1.6 0.2 0.2
Mitogen-Act protein kinase 3 isoform 1 MAPK3 Act IADPEHDHTGFLTEpYVATR 1.8 1.1 0.6 Act IADPEHDHTGFLpTEpYVATR 8.0 2.9 0.4
Syntaxin-5 STX5 Act YGpSKNTDQGVYLGLSK 2.4 1.0 0.4 DENN domain-containing protein 4C DENND4C Act STpSLSALVR 2.7 1.0 0.4 Eukaryotic elongation factor 2 kinase EEF2K Act YpSSSGpSPANSFHFK 1.7 0.6 0.3 Cyclin-L1 CCNL1 Act GLNPDGTPALSTLGGFpSPASKPpSpSPR 1.7 0.8 0.5 Glucose-6-phosphate 1-dehydrogenase isoform a G6PD Unc VGFQYEGTpYK 1.9 0.7 0.4 Utrophin UTRN Unc IEQYApTR 1.7 0.9 0.6 Tight junction protein ZO-1 isoform a TJP1 Unc YESSSpYTDQFSR 4.4 1.4 0.3
Junction plakoglobin JUP Unc
VTEWQQTpYTYDSGIHSGANTCVPSVSSK
3.3 1.0 0.3
Catenin delta-1 isoform 1ABC CTNND1
Unc HYEDGYPGGSDNpYGpSLSR 2.3 1.1 0.5
Unc
SM(ox)GYDDLDpYGM(ox)M(ox)SDYGTAR
2.2 1.2 0.6
Unc LNGPQDHSHLLpYSTIPR 2.1 1.4 0.6 Unc QDVpYGPQPQVR 1.4 0.9 0.6
Catenin beta-1 CTNNB1 Unc
AAVSHWQQQSpYLDSGIHSGATTTAPSLSGK
2.5 1.0 0.4
Disks large homolog 1 isoform 2 DLG1 Unc DYEVDGRDpYHFVTSR 1.5 0.9 0.6 Anion exchange protein 2 SLC4A2 Unc SYGEEDFEpYHR 1.7 0.9 0.5 Protein TANC2 TANC2 Unc TNNAQNGHLLEDDpYYSPHGMLANGSR 3.1 1.3 0.4 Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide
DAPP1 Unc KVEEPSIYEpSVR 45.2 1.2 0.0
Kin of IRRE-like protein 1 precursor KIRREL Unc AVLYADpYRAPGPAR 2.3 1.2 0.6
Probable ATP-dependent RNA helicase DHX36 isoform 1 DHX36 Unc (ac)SYDpYHQNWGR 1.2 0.7 0.6
Protein S100-A16 S100A16 Unc YVSKYpSLVK 1.6 0.7 0.4 Ras-related protein Rab-11B RAB11B Unc (ac)GTRDDEpYDYLFK 3.4 1.1 0.4 SHC-transforming protein 1 isoform 3 SHC1 Unc ELFDDPpSYVNVQNLDK 1.7 0.7 0.4
115
PDZ and LIM domain protein 5 isoform a PDLIM5 Unc YTEFpYHVPTHSDASK 2.1 0.9 0.5
Receptor-type tyrosine-protein phosphatase kappa isoform a PTPRK Unc YLCEGTESPpYQTGQLHPAIR 2.4 1.2 0.5
Mitogen-Act protein kinase 7 isoform 1 MAPK7 Unc GLCTSPAEHQYFMTEpYVATR 5.3 0.9 0.2 Mitogen-Act protein kinase 14 isoform 2 MAPK14 Unc HTDDEMpTGpYVATR 2.5 1.1 0.5 Partitioning defective 3 homolog isoform 1 PARD3 Unc FSPDSQpYIDNR 1.2 0.9 0.6 SH2 domain-containing protein 4A isoform a SH2D4A Unc SQpYHDLQAPDNQQTK 2.8 1.5 0.6
Signal transducer and activator of transcription 3 isoform 2 STAT3 Unc YCRPESQEHPEADPGAAPpYLK 1.4 0.7 0.6
Caskin-2 isoform a CASKIN2 Unc NTpYNQTALDIVNQFTTSQASR 1.0 0.7 0.7
Tight junction protein ZO-2 isoform 3 TJP2 Unc RHQYSDYDpYHSSSEK 6.3 1.2 0.2 Unc MSYLTAMGADpYLSCDSR 3.2 1.0 0.3 Unc HQYSDpYDYHSSSEK 1.9 1.1 0.6
Epidermal growth factor receptor isoform a precursor EGFR Unc GSHQIpSLDNPDpYQQDFFPK 2.0 1.1 0.6
PREDICTED: occludin-like - Unc NVSAGTQDVPSPPpSDYVER 1.1 0.7 0.6 Protein kinase C delta type PRKCD Unc SDSASSEPVGIpYQGFEKK 2.3 1.2 0.6 DNAJ homolog subfamily A member 1 DNAJA1 Unc HYNGEApYEDDEHHPR 3.1 1.0 0.4 Oligophrenin-1 OPHN1 Unc LWMEAMDGKEPIpYHSPITK 2.7 0.8 0.3 Mitogen-Act protein kinase 13 MAPK13 Unc HADAEMTGYVVpTR 2.2 1.3 0.6 Receptor-type tyrosine-protein phosphatase alpha isoform 1 precursor
PTPRA Unc VVQEYIDAFSDpYANFK 1.2 0.7 0.7
Myelin protein zero-like protein 1 isoform a MPZL1 Unc SESVVpYADIR 1.3 0.8 0.5 U1 small nuclear ribonucleoprotein C SNRPC Unc FYCDpYCDTYLTHDSPSVR 3.2 1.2 0.4 Lipolysis-stimulated lipoprotein receptor isoform 2 LSR Unc SSSAGGQGSpYVPLLR 2.7 1.4 0.5 GRB2-associated-binding protein 1 isoform a GAB1 Unc GDKQVEpYLDLDLDSGK 3.7 0.7 0.2 Alpha-endosulfine isoform 3 ENSA Unc GQKpYFDSGDYNMAK 4.4 0.8 0.2
Phosphatidylinositol 3-kinase regulatory subunit beta PIK3R2 Unc EYDQLYEEYpTR 2.1 0.8 0.4
Cofilin-1 CFL1 Unc HELQANCpYEEVKDR 1.3 0.7 0.6 Fotillin-1 FLOT1 Unc RAQADLApYQLQVAK 3.7 0.9 0.3 Annexin A2 isoform 1 ANXA2 Unc LSLEGDHSTPPSApYGSVK 1.3 0.8 0.7 Protein-tyrosine kinase 6 PTK6 Unc ERLSSFTpSYENPT 1.3 0.7 0.6
Plakophilin-4 isoform a PKP4 Unc LQHQQLpYYSQDDSNRK 2.4 1.0 0.5 Unc SPNHGTVELQGSQTALpYR 1.0 0.8 0.6 Unc QTSNPNGPTPQpYQTTAR 1.2 1.3 0.6
E3 ubiquitin-protein ligase CBL-B CBLB Unc VFSNGHLGpSEEYDVPPR 5.1 1.3 0.3
Receptor tyrosine-protein kinase erbB-3 isoform 1 precursor ERBB3 Unc SLEATDSAFDNPDYWHpSR 2.2 0.8 0.4
Unc SLEATDSAFDNPDpYWHSR 1.6 0.7 0.4
116
Epidermal growth factor receptor kinase substrate 8 EPS8 Unc LSTEHSSVSEpYHPADGYAFSSNIYTR 2.6 0.8 0.3 Act CDC42 kinase 1 isoform 2 TNK2 Unc VSSTHYpYLLPERPSYLER 4.5 0.7 0.2
Plakophilin-3 PKP3 Unc GQpYHTLQAGFSSR 6.9 1.4 0.2 Unc ADpYDTLSLR 2.3 0.7 0.3
Neuroblast differentiation-associated protein AHNAK isoform 1 AHNAK Unc VKGEYDMpTVPK 2.0 0.7 0.4
Phosphoprotein associated with glycosphingolipid-enriched microdomains 1
PAG1
Unc SPSSCNDLpYATVK 2.5 1.1 0.5
Unc SGQSLTVPESTpYTSIQGDPQR 2.1 1.2 0.5
Unc SVDGDQGLGMEGPpYEVLK 1.4 0.9 0.7
Rho GTPase-activating protein 5 isoform a ARHGAP5 Unc GYSDEIpYVVPDDSQNR 2.6 0.9 0.4 Lysosomal-associated transmembrane protein 4A LAPTM4A Unc MPEKEPPPPpYLPA 1.7 0.7 0.4
Staphylococcal nuclease domain-containing protein 1 SND1 Unc YGDFRADDADEFGpYSR 4.0 1.4 0.4
Breakpoint cluster region protein isoform 1 BCR Unc SSESSCGVDGDpYEDAELNPR 3.0 1.2 0.3 Protein CDV3 homolog isoform b CDV3 Unc LQLDNQpYAVLENQK 1.7 0.8 0.5 Protein LAP2 isoform 2 ERBB2IP Unc IpYDILSDNGPQQPSTTVK 2.6 1.4 0.6 Brain-specific angiogenesis inhibitor 1-associated protein 2 isoform 2
BAIAP2 Unc LSDSpYSNTLPVRK 2.6 0.7 0.3
Tyrosine-protein kinase JAK1 JAK1 Act AIETDKEpYYTVK 6.7 3.3 0.6 Leucine-rich repeat and fibronectin type-III domain-containing protein 6
ELFN2 Act DSTpYSQLSPR 6.1 3.8 0.6
Tight junction protein ZO-1 isoform a TJP1 Act LSYLSAPGSEpYSMYSTDSR 3.7 1.7 0.6 Act QYFEQpYSR 6.4 3.9 0.6
PDZ and LIM domain protein 1 PDLIM1 Act ERVTPPEGYEVVpTVFPK 3.0 2.0 0.7 BAG family molecular chaperone regulator 3 BAG3 Act THYPAQQGEYQTHQPVpYHK 2.6 1.5 0.6
Catenin delta-1 isoform 1ABC CTNND1 Act YRPSMEGpYR 6.2 1.6 0.3 Act SMGpYDDLDYGMMSDYGTAR 4.9 1.5 0.3 Act NGNGGPGPpYVGQAGTATLPR 2.9 1.8 0.7
Plakophilin-2 isoform 2b PKP2 Act TSSVPEpYVYNLHLVENDFVGGR 4.9 2.0 0.4 Epsin-2 isoform a EPN2 Act AGGSPASpYHGSTSPR 11.3 7.5 0.7 Transmembrane channel-like protein 5 isoform a TMC5 Act SLSNPDpYSGTR 4.0 2.6 0.7 Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide
DAPP1 Act KVEEPSIpYESVR 25.2 3.1 0.1
Probable ATP-dependent RNA helicase DDX6 DDX6 Act SLYVAEYHpSEPVEDEKP 4.7 2.9 0.7 Kin of IRRE-like protein 1 precursor KIRREL Act LSHSSGpYAQLNTYSR 2.8 1.6 0.6 Signal transducing adapter molecule 2 STAM2 Act SLpYPSSEIQLNNK 4.6 2.9 0.6
Hepatocyte growth factor receptor isoform a precursor MET Act SVpSPTTEM(ox)VSNESVDpYR 4.5 2.6 0.6
117
Act SVSPTTEM(ox)VSNESVDpYR 3.3 2.0 0.6
SHC-transforming protein 1 isoform 3 SHC1 Act FKQpYLR 11.4 7.2 0.7 TBC1 domain family member 5 isoform a TBC1D5 Act (ac)M(ox)pYHSLSETR 2.4 1.7 0.7 Mitogen-Act protein kinase 1 MAPK1 Act VADPDHDHpTGFLTEpYVATR 14.5 6.7 0.5
Signal transducer and activator of transcription 3 isoform 2 STAT3 Act LLGPGVNpYSGCQITWAK 11.0 4.1 0.4
Signal transducer and activator of transcription 5A STAT5A Act AVDGpYVKPQIK 18.7 7.1 0.4 Rho GTPase-activating protein 32 isoform 1 ARHGAP32 Act QSSVTVVSQYDNLEDpYHSLPQHQR 3.0 1.7 0.6 Filamin-B isoform 1 FLNB Act SSTETCpYSAIPK 3.8 2.2 0.7 Rho GTPase-activating protein 12 ARHGAP12 Act ATTPPNQGRPDSPVpYANLQELK 3.6 2.5 0.7 Zinc finger CCCH-type antiviral protein 1 isoform 1 ZC3HAV1 Act KGTGLLSSDpYR 4.1 2.6 0.6
Tight junction protein ZO-2 isoform 3 TJP2 Act SIDQDpYER 3.5 2.1 0.6 Act TFLRPSPEDEAIpYGPNTK 3.0 1.9 0.6
Epidermal growth factor receptor isoform a precursor EGFR Act MHLPSPTDSNFpYR 2.8 1.8 0.7
1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-1 isoform a
PLCG1 Act IGTAEPDpYGALYEGR 6.2 3.4 0.6
Protein sprouty homolog 1 SPRY1 Act GSNEpYTEGPSVVK 9.1 1.5 0.3 Plectin isoform 1 PLEC Act GYYSPpYSVSGSGSTAGSR 5.4 3.8 0.6 Calmodulin CALM2 Act VFDKDGNGpYISAAELR 5.8 2.8 0.5 Lipolysis-stimulated lipoprotein receptor isoform 2 LSR Act VLpYYMEK 2.7 1.6 0.6 GRB2-associated-binding protein 1 isoform a GAB1 Act HGMNGFFQQQM(ox)IpYDSPPSR 3.0 1.8 0.6 Ras-associated and pleckstrin homology domains-containing protein 1 isoform 1
RAPH1 Act AGYGGSHIpSGYATLR 9.7 6.1 0.7
Crk-like protein CRKL Act VPCApYDK 5.0 3.1 0.7 Protein sprouty homolog 2 SPRY2 Act NTNEpYTEGPTVVPR 4.4 2.1 0.5 Actin filament-associated protein 1-like 2 isoform 1 AFAP1L2 Act TDPEEFTYDpYVDADR 3.3 2.1 0.7
Plakophilin-4 isoform a PKP4
Act TYYpSPVYR 2.6 1.6 0.6 Act TYpYSPVYR 2.5 1.6 0.6 Act VQECNpYNR 6.6 3.3 0.6
Receptor tyrosine-protein kinase erbB-3 isoform 1 precursor ERBB3 Act AFQGPGHQAPHVHpYAR 11.2 7.1 0.7
Desmoplakin isoform I DSP Act GVITDQNSDGpYCQTGTMSR 4.3 2.5 0.6 Uveal autoantigen with coiled-coil domains and ankyrin repeats isoform 1
UACA Act FKpYFESDHLGSGSHFSNR 5.8 3.8 0.7
Neuroblast differentiation-associated protein AHNAK isoform 1
AHNAK
Act RVpTAYpTVDVTGR 10.4 1.8 0.2
Act VKGEpYDVTVPK 5.2 2.5 0.5
118
Phosphoprotein associated with glycosphingolipid-enriched microdomains 1
PAG1 Act AEFAEpYASVDR 2.8 1.5 0.6
Tensin-3 TNS3 Act ETMTPGpYPQDLDIIDGR 2.5 1.5 0.7 Mucin-1 isoform 1 precursor MUC1 Act YVPPSSTDRSPpYEK 2.6 1.7 0.6 ATP-dependent RNA helicase DDX3X isoform 1 DDX3X Act SDpYDGIGSR 5.4 3.0 0.6
Protein LAP2 isoform 2 ERBB2IP
Act
MPLSNGQMGQPLRPQANpYSQIHHPPQASVAR
5.4 3.0 0.6
Act VAHQPPpYTQPHCSPR 7.5 4.4 0.6 Act EQLIDpYLM(ox)LK 6.2 2.8 0.6 Act TM(ox)SVSDFNpYSR 6.0 3.3 0.6 Act ANTApYHLHQR 5.5 3.6 0.6
Mitogen-Act protein kinase 3 isoform 1 MAPK3 Act IADPEHDHTGFLpTEYVATR 4.4 2.2 0.5
119
Molecular Class
Number of molecules
Kinase 48 Adapter molecule 39 Transcription regulatory protein 28 Cytoskeletal associated protein 25 GTPase activating protein 24 Transport/cargo protein 21 Adhesion molecule 20 Cell junction protein 17 Transcription factor 16 Enzymes 13 Integral membrane protein 12 RNA binding protein 11 Structural protein 10 Calcium binding protein 10 Anchor protein 10 Membrane transport protein 8 ATPase 8 Ubiquitin proteasome system protein 7 Translation regulatory protein 5 Cell cycle control protein 5 Guanine nucleotide exchange factor 4 DNA binding protein 4 Chaperone 4 RNA helicase 3 Regulatory/other subunit 3 Protease inhibitor 3 Receptor tyrosine phosphatase 2 Motor protein 2 Unclassified 128 Others 9
Table B: List of molecules identified from each category classified based on molecular class